文献速递临床试验与 GCP流行病学与生物统计

双序贯体外除颤治疗难治性心室颤动(DOSE VF):随机对照试验研究方案

DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation (DOSE VF): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-11-26

本研究为三臂整群随机交叉试验,在加拿大安大略省六个地区开展,纳入院外心脏骤停后难治性室颤或无脉性室速的成人患者,比较双序贯体外除颤(DSED)、向量改变(VC)除颤与标准除颤对出院存活率的影响。主要结局为出院存活率,次要结局包括自主循环恢复、室颤终止及除颤次数等。

要点

  • DSED和VC除颤是难治性室颤的潜在替代策略,但证据尚不充分。
  • 试验采用整群随机交叉设计,在六个地区比较三种除颤策略。
  • 主要结局为出院存活率,并将进行早期与晚期DSED的亚组分析。

核心结论

  • 需设计严谨的随机对照试验以明确DSED或VC除颤是否改善难治性室颤患者的临床结局。

研究设计与样本

  • 三臂整群随机交叉试验,在加拿大安大略省六个地区开展,为期3年。
  • 纳入年龄≥18岁、院外心脏骤停且疑为心源性病因、连续三次标准除颤后仍为室颤/无脉性室速的成人患者。
  • 患者接受标准除颤、DSED或VC除颤(除颤电极从前后位改为前后位)三种策略之一。

关键数值与推荐

  • 难治性室颤定义为连续三次标准除颤尝试后仍为室颤/无脉性室速。
  • 主要结局为出院存活率。
  • 次要结局包括自主循环恢复、首次干预性电击后室颤终止、所有干预性电击后室颤终止及获得自主循环恢复所需的除颤次数。
  • 预先设定亚组分析比较早期DSED(首次DSED电击为第4-6次电击)与晚期DSED(首次DSED电击为第7次或以后)的存活率。

临床怎么用

  • 对于院外心脏骤停后难治性室颤患者,DSED和VC除颤可作为标准除颤之外的候选干预策略,但其临床效果需待本试验结果验证。

局限性

  • 研究方案阶段,尚无结果数据;原文未报告样本量、效应值或统计效能等具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite high-quality cardiopulmonary resuscitation (CPR), early defibrillation, and antiarrhythmic medications, some patients remain in refractory ventricular fibrillation (VF) during out-of-hospital cardiac arrest. These patients have worse outcomes compared to patients who respond to initial treatment. Double sequential external defibrillation (DSED) and vector change (VC) defibrillation have been proposed as viable options for patients in refractory VF. However, the evidence supporting the use of novel defibrillation strategies is inconclusive. The objective of this study is to compare two novel therapeutic defibrillation strategies (DSED and VC) against standard defibrillation for patients with treatment refractory VF or pulseless ventricular tachycardia (pVT) during out-of-hospital cardiac arrest. RESEARCH QUESTION: Among adult (≥ 18 years) patients presenting in refractory VF or pulseless ventricular tachycardia (pVT) during out-of-hospital cardiac arrest, does DSED or VC defibrillation result in greater rates of survival to hospital discharge compared to standard defibrillation? METHODS: This will be a three-arm, cluster randomized trial with repeated crossover conducted in six regions of Ontario, Canada (Peel, Halton, Toronto, Simcoe, London, and Ottawa), over 3 years. All adult (≥ 18 years) patients presenting in refractory VF (defined as patients presenting in VF/pVT and remaining in VF/pVT after three consecutive standard defibrillation attempts during out-of-hospital cardiac arrest of presumed cardiac etiology will be treated by one of three strategies: (1) continued resuscitation using standard defibrillation, (2) resuscitation involving DSED, or (3) resuscitation involving VC (change of defibrillation pads from anterior-lateral to anterior-posterior pad position) defibrillation. The primary outcome will be survival to hospital discharge. Secondary outcomes will include return of spontaneous circulation (ROSC), VF termination after the first interventional shock, VF termination inclusive of all interventional shocks, and number of defibrillation attempts to obtain ROSC. We will also perform an a priori subgroup analysis comparing rates of survival for those who receive "early DSED," or first DSED shock is shock 4-6, to those who receive "late DSED," or first DSED shock is shock 7 or later. DISCUSSION: A well-designed randomized controlled trial employing a standardized approach to alternative defibrillation strategies early in the treatment of refractory VF is urgently required to determine if the treatments of DSED or VC defibrillation impact clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04080986 . Registered on 6 September 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Drennan IR, Dorian P, McLeod S, et al. DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation (DOSE VF): study protocol for a randomized controlled trial. Trials. 2020. PMID: 33243277. doi:10.1186/s13063-020-04904-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。